NASDAQ:EGRXEagle Pharmaceuticals Competitors & Alternatives

Eagle Pharmaceuticals (NASDAQ:EGRX) and Amarin (NASDAQ:AMRN) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership.

Earnings and Valuation

This table compares Eagle Pharmaceuticals and Amarin's revenue, earnings per share (EPS) and valuation.

Eagle Pharmaceuticals has higher earnings, but lower revenue than Amarin. Amarin is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

96.0% of Eagle Pharmaceuticals shares are held by institutional investors. Comparatively, 44.4% of Amarin shares are held by institutional investors. 21.1% of Eagle Pharmaceuticals shares are held by company insiders. Comparatively, 2.8% of Amarin shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Risk and Volatility

Eagle Pharmaceuticals has a beta of 1.02, indicating that its share price is 2% more volatile than the S&P 500. Comparatively, Amarin has a beta of 2.72, indicating that its share price is 172% more volatile than the S&P 500.

Profitability

This table compares Eagle Pharmaceuticals and Amarin's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current ratings and price targets for Eagle Pharmaceuticals and Amarin, as reported by MarketBeat.

Eagle Pharmaceuticals presently has a consensus price target of $52.50, indicating a potential upside of 8.36%. Amarin has a consensus price target of $17.2308, indicating a potential upside of 156.41%. Given Amarin's stronger consensus rating and higher probable upside, analysts clearly believe Amarin is more favorable than Eagle Pharmaceuticals.

Summary

Eagle Pharmaceuticals beats Amarin on 8 of the 14 factors compared between the two stocks.

Eagle Pharmaceuticals (NASDAQ:EGRX) and Karuna Therapeutics (NASDAQ:KRTX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

Analyst Ratings

This is a breakdown of current ratings for Eagle Pharmaceuticals and Karuna Therapeutics, as reported by MarketBeat.

Eagle Pharmaceuticals presently has a consensus price target of $52.50, indicating a potential upside of 8.36%. Karuna Therapeutics has a consensus price target of $117.7273, indicating a potential upside of 20.35%. Given Karuna Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Karuna Therapeutics is more favorable than Eagle Pharmaceuticals.

Insider & Institutional Ownership

96.0% of Eagle Pharmaceuticals shares are owned by institutional investors. Comparatively, 63.9% of Karuna Therapeutics shares are owned by institutional investors. 21.1% of Eagle Pharmaceuticals shares are owned by insiders. Comparatively, 18.1% of Karuna Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Eagle Pharmaceuticals and Karuna Therapeutics' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Eagle Pharmaceuticals and Karuna Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Eagle Pharmaceuticals has higher revenue and earnings than Karuna Therapeutics. Karuna Therapeutics is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Eagle Pharmaceuticals beats Karuna Therapeutics on 9 of the 12 factors compared between the two stocks.

Eagle Pharmaceuticals (NASDAQ:EGRX) and Taro Pharmaceutical Industries (NYSE:TARO) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

Profitability

This table compares Eagle Pharmaceuticals and Taro Pharmaceutical Industries' net margins, return on equity and return on assets.

Insider and Institutional Ownership

96.0% of Eagle Pharmaceuticals shares are owned by institutional investors. Comparatively, 11.6% of Taro Pharmaceutical Industries shares are owned by institutional investors. 21.1% of Eagle Pharmaceuticals shares are owned by insiders. Comparatively, 13.8% of Taro Pharmaceutical Industries shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations and price targets for Eagle Pharmaceuticals and Taro Pharmaceutical Industries, as reported by MarketBeat.com.

Eagle Pharmaceuticals currently has a consensus price target of $52.50, indicating a potential upside of 8.36%. Taro Pharmaceutical Industries has a consensus price target of $96.00, indicating a potential upside of 47.40%. Given Taro Pharmaceutical Industries' stronger consensus rating and higher probable upside, analysts clearly believe Taro Pharmaceutical Industries is more favorable than Eagle Pharmaceuticals.

Earnings and Valuation

This table compares Eagle Pharmaceuticals and Taro Pharmaceutical Industries' gross revenue, earnings per share (EPS) and valuation.

Taro Pharmaceutical Industries has higher revenue and earnings than Eagle Pharmaceuticals. Taro Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Eagle Pharmaceuticals has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Comparatively, Taro Pharmaceutical Industries has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500.

Summary

Taro Pharmaceutical Industries beats Eagle Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

Eagle Pharmaceuticals (NASDAQ:EGRX) and Pacira Biosciences (NASDAQ:PCRX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, analyst recommendations, profitability, dividends and risk.

Valuation and Earnings

This table compares Eagle Pharmaceuticals and Pacira Biosciences' top-line revenue, earnings per share (EPS) and valuation.

Eagle Pharmaceuticals has higher earnings, but lower revenue than Pacira Biosciences. Eagle Pharmaceuticals is trading at a lower price-to-earnings ratio than Pacira Biosciences, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

96.0% of Eagle Pharmaceuticals shares are owned by institutional investors. 21.1% of Eagle Pharmaceuticals shares are owned by insiders. Comparatively, 5.8% of Pacira Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations and price targets for Eagle Pharmaceuticals and Pacira Biosciences, as provided by MarketBeat.com.

Eagle Pharmaceuticals currently has a consensus target price of $52.50, suggesting a potential upside of 8.36%. Pacira Biosciences has a consensus target price of $58.7857, suggesting a potential upside of 2.20%. Given Eagle Pharmaceuticals' higher possible upside, equities analysts clearly believe Eagle Pharmaceuticals is more favorable than Pacira Biosciences.

Risk and Volatility

Eagle Pharmaceuticals has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Comparatively, Pacira Biosciences has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500.

Profitability

This table compares Eagle Pharmaceuticals and Pacira Biosciences' net margins, return on equity and return on assets.

Eagle Pharmaceuticals (NASDAQ:EGRX) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation and risk.

Risk and Volatility

Eagle Pharmaceuticals has a beta of 1.02, indicating that its share price is 2% more volatile than the S&P 500. Comparatively, Apellis Pharmaceuticals has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for Eagle Pharmaceuticals and Apellis Pharmaceuticals, as provided by MarketBeat.

Eagle Pharmaceuticals presently has a consensus price target of $52.50, indicating a potential upside of 8.36%. Apellis Pharmaceuticals has a consensus price target of $51.00, indicating a potential upside of 57.16%. Given Apellis Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Apellis Pharmaceuticals is more favorable than Eagle Pharmaceuticals.

Valuation & Earnings

This table compares Eagle Pharmaceuticals and Apellis Pharmaceuticals' gross revenue, earnings per share and valuation.

Eagle Pharmaceuticals has higher revenue and earnings than Apellis Pharmaceuticals. Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

96.0% of Eagle Pharmaceuticals shares are owned by institutional investors. Comparatively, 72.6% of Apellis Pharmaceuticals shares are owned by institutional investors. 21.1% of Eagle Pharmaceuticals shares are owned by insiders. Comparatively, 9.5% of Apellis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Eagle Pharmaceuticals and Apellis Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Eagle Pharmaceuticals beats Apellis Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

SAGE Therapeutics (NASDAQ:SAGE) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings for SAGE Therapeutics and Eagle Pharmaceuticals, as provided by MarketBeat.

SAGE Therapeutics presently has a consensus target price of $82.1111, indicating a potential upside of 91.31%. Eagle Pharmaceuticals has a consensus target price of $52.50, indicating a potential upside of 8.36%. Given SAGE Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe SAGE Therapeutics is more favorable than Eagle Pharmaceuticals.

Volatility and Risk

SAGE Therapeutics has a beta of 2.68, meaning that its share price is 168% more volatile than the S&P 500. Comparatively, Eagle Pharmaceuticals has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500.

Earnings & Valuation

This table compares SAGE Therapeutics and Eagle Pharmaceuticals' gross revenue, earnings per share and valuation.

Eagle Pharmaceuticals has higher revenue and earnings than SAGE Therapeutics. SAGE Therapeutics is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares SAGE Therapeutics and Eagle Pharmaceuticals' net margins, return on equity and return on assets.

Institutional and Insider Ownership

96.0% of Eagle Pharmaceuticals shares are owned by institutional investors. 4.8% of SAGE Therapeutics shares are owned by insiders. Comparatively, 21.1% of Eagle Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Eagle Pharmaceuticals beats SAGE Therapeutics on 9 of the 14 factors compared between the two stocks.